PHIO PHARMACEUTICALS CORP. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate
PHIO PHARMACEUTICALS CORP. (PHIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate of 98.87% for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-14.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate · last filed 2019-05-14
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2019-03-31 was 98.87%, a 8.20% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2018-09-30 was 161.45%, a 83.61% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2018-06-30 was 95.77%, a 12.00% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2018-03-31 was 91.38%, a 8.49% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2018 was 159.55%, a 88.48% increase from fiscal 2017.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2017 was 84.65%, a 5.02% decline from fiscal 2016.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2016 was 89.12%, a 0.16% decline from fiscal 2015.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2015 was 89.26%, a 12.08% decline from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 12 month |
|---|---|---|---|---|---|---|
| 2019-03-31 | 98.87% 10-Q · filed 2019-05-14 | |||||
| 2018-12-31 | 159.55% 10-K · filed 2019-03-27 | |||||
| 2018-09-30 | 161.45% 10-Q · filed 2018-11-14 | 159.55% 10-Q · filed 2018-11-14 | ||||
| 2018-06-30 | 95.77% 10-Q · filed 2018-08-14 | 92.84% 10-Q · filed 2018-08-14 | ||||
| 2018-03-31 | 91.38% 10-Q · filed 2019-05-14 | |||||
| 2017-12-31 | 84.65% 10-K · filed 2019-03-27 | |||||
| 2017-09-30 | 87.93% 10-Q · filed 2018-11-14 | 84.65% 10-Q · filed 2018-11-14 | ||||
| 2017-06-30 | 85.51% 10-Q · filed 2018-08-14 | 84.63% 10-Q · filed 2018-08-14 | ||||
| 2017-03-31 | 84.23% 10-Q · filed 2018-05-10 | |||||
| 2016-12-31 | 89.12% 10-K · filed 2018-03-26 | |||||
| 2016-09-30 | 116.88% 10-Q · filed 2016-11-10 | 89.12% 10-Q/A · filed 2018-03-26 | ||||
| 2016-06-30 | 88.64% 10-Q/A · filed 2018-03-26 | |||||
| 2016-03-31 | 88.64% 10-Q/A · filed 2018-03-26 | |||||
| 2015-12-31 | 89.26% 10-K · filed 2017-03-30 | |||||
| 2015-09-30 | 107.49% 10-Q · filed 2016-11-10 | 89.43% 10-Q · filed 2016-11-10 | ||||
| 2015-06-30 | 86.85% 10-Q · filed 2016-08-11 | 87.62% 10-Q · filed 2016-08-11 | ||||
| 2015-03-31 | 90.29% 10-Q · filed 2016-05-12 | |||||
| 2014-12-31 | 101.52% 10-K · filed 2016-03-30 | |||||
| 2014-09-30 | 103.47% 10-Q · filed 2015-11-12 | 101.50% 10-Q · filed 2015-11-12 | ||||
| 2014-06-30 | 100.77% 10-Q · filed 2015-08-12 | 101.19% 10-Q · filed 2015-08-12 | 100.95% 10-Q · filed 2014-08-14 | |||
| 2014-03-31 | 107.01% 10-Q · filed 2015-05-13 | 106.64% 10-Q · filed 2014-05-14 | ||||
| 2013-12-31 | 76.27% 10-K · filed 2015-03-30 | |||||
| 2013-09-30 | 107.30% 10-Q · filed 2014-11-13 | 76.27% 10-Q · filed 2014-11-13 | ||||
| 2013-06-30 | 75.53% 10-Q · filed 2014-08-14 | 75.53% 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |